Page 182 - Haematologica March 2020

C. Annageldiyev et al.
20. Pandey MK, Gowda K, Sung SS, et al. A
novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis. Exp Hematol. 2017;53:31-42.
21. Kawakami Y, Inagaki N, Salek-Ardakani S, et al. Regulation of dendritic cell matura- tion and function by Bruton's tyrosine kinase via IL-10 and Stat3. Proc Natl Acad Sci U S A. 2006;103(1):153-158.
22. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. Stat3 signaling in acute myeloid leukemia: ligand-dependent and - independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011;117(21):5701-5709.
23. Kanna R, Choudhary G, Ramachandra N, et al. STAT3 inhibition as a therapeutic strategy for leukemia. Leuk Lymphoma. 2018;59(9):2068-2074.
24. Blume R, Rempel E, Manta L, et al. The molecular signature of AML with increased ALDH activity suggests a stem cell origin. Leuk Lymphoma. 2018;59(9):2201-2210.
25. Gasparetto M, Smith CA. ALDHs in nor- mal and malignant hematopoietic cells: Potential new avenues for treatment of AML and other blood cancers. Chem Biol Interact. 2017;276:46-51.
26. Bogen A, Buske C, Hiddemann W, Bohlander SK, Christ O. Variable aldehyde dehydrogenase activity and effects on chemosensitivity of primitive human leukemic cells. Exp Hematol. 2017;47:54- 63.
27. Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood. 2014;123(8):1229-1238.
28. Li X, Yin X, Wang H, et al. The combina- tion effect of homoharringtonine and ibru- tinib on FLT3-ITD mutant acute myeloid leukemia. Oncotarget. 2017;8(8):12764- 12774.
29. Dicke KA, Spitzer G, Scheffers PH, et al. In vitro colony growth of acute myelogenous leukemia. Hamatol Bluttransfus. 1976; 19:63-77.
30. Pollyea DA, Jordan CT. Therapeutic target- ing of acute myeloid leukemia stem cells. Blood. 2017;129(12):1627-1635.
31. Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem
cells. Blood. 2017;129(12):1577-1585.
32. Du X, Li Y, Xia YL, et al. Insights into Protein-Ligand Interactions: Mechanisms, Models, and Methods. Int J Mol Sci. 2016;
17(2).
33. Smith C, Gasparetto M, Humphries K, et
tion. Blood. 2015;125(12):1936-1947.
45. Smith CI, Baskin B, Humire-Greiff P, et al. Expression of Bruton's agammaglobuline- mia tyrosine kinase gene, BTK, is selective- ly down-regulated in T lymphocytes and plasma cells. J Immunol. 1994;152(2):557-
al. Aldehyde dehydrogenases in acute 565.
myeloid leukemia. Ann N Y Acad Sci. 2014;
1310:58-68.
34. Hoang VT, Hoffmann I, Borowski K, et al.
Identification and separation of normal hematopoietic stem cells and leukemia stem cells from patients with acute myeloid leukemia. Methods Mol Biol. 2013;1035:217-230.
35. Kastan MB, Schlaffer E, Russo JE, et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood. 1990;75(10):1947- 1950.
36. Lowenberg B, Rowe JM. Introduction to the review series on advances in acute myeloid leukemia (AML). Blood. 2016; 127(1):1.
37. Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112(13):4793-4807.
38. Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in progress. Lab Invest. 2006;86(12):1203- 1207.
39. Lacerda L, Pusztai L, Woodward WA. The role of tumor initiating cells in drug resist- ance of breast cancer: Implications for future therapeutic approaches. Drug Resist Updat. 2010;13(4-5):99-108.
40. Wang JC, Dick JE. Cancer stem cells: les- sons from leukemia. Trends Cell Biol. 2005;15(9):494-501.
41. Krause DS, Van Etten RA. Right on target: eradicating leukemic stem cells. Trends Mol Med. 2007;13(11):470-481.
42. Gu TL, Nardone J, Wang Y, et al. Survey of activated FLT3 signaling in leukemia. PLoS One. 2011;6(4):e19169.
43. Tomasson MH, Xiang Z, Walgren R, et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood. 2008; 111(9):4797-4808.
44. Oellerich T, Mohr S, Corso J, et al. FLT3- ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and prolifera-
46. Rezvani K, Barrett J. STAT3: the "Achilles" heel for AML? Blood. 2014;123(1):1-2.
47. Steensma DP, McClure RF, Karp JE, et al.
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activa- tion is common and remains unexplained. Leukemia. 2006;20(6):971-978.
48. Benekli M, Xia Z, Donohue KA, et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 2002;99(1):252-257.
49. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106(12):3747- 3754.
50. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776-2784.
51. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006; 107(10):4011-4020.
52. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predic- tors of favorable prognosis in acute myel- ogenous leukemia with a normal kary- otype. Blood. 2005;106(12):3733-3739.
53. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cyto- genetics: interaction with other gene muta- tions. Blood. 2005;106(12):3740-3746.
54. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood. 2005;106(8):2854-2861.
696
haematologica | 2020; 105(3)